Armata Pharmaceuticals, Inc. (ARMP): debt financing — Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva

Armata Pharmaceuticals, Inc.

2025-Q2 EPS reported -$0.63 vs consensus -$0.40 ▼ miss (-58.4%)

Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.
Entered $15M secured credit agreement with Innoviva at 14% interest, matures Jan 2029; proceeds to fund AP-SA02 development.
Positive topline results from Phase 1b/2a diSArm trial: met primary endpoints, improved clinical outcomes, no treatment-related SAEs.
Received additional $4.65M non-dilutive funding from U.S. Department of Defense through MTEC.
Plans end-of-Phase 2 meeting with FDA in H2 2025; expects to start Phase 3 pivotal trial in 2026.

item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Armata Pharmaceuticals, Inc. incurred term loan of $15 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.

Instrument: term loan
Principal: $15 million
Counterparty: Innoviva Strategic Opportunities LLC
Rate: 14.0% per annum
Maturity: January 11, 2029
Event: incurrence

Exact text from the filing

The August 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $15 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.

View on SEC.gov

73 debt financings filed in the last 30 days. Browse all debt financings →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-011227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.